Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,073 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.
Kai M, Hikita H, Kazuki M, Tahata Y, Shinkai K, Doi A, Ohkawa K, Miyazaki M, Ishida H, Matsumoto K, Nozaki Y, Yakushijin T, Sakamori R, Kaneko A, Iio S, Nawa T, Kakita N, Morishita N, Hiramatsu N, Usui T, Imanaka K, Doi Y, Sakakibara M, Yoshida Y, Oze T, Kodama T, Tatsumi T, Takehara T. Kai M, et al. Among authors: doi y, doi a. PLoS One. 2024 Jan 2;19(1):e0294590. doi: 10.1371/journal.pone.0294590. eCollection 2024. PLoS One. 2024. PMID: 38165900 Free PMC article.
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Ohkawa K, Oshita M, Miyazaki M, Yakushijin T, Nozaki Y, Matsumoto K, Tanaka S, Kaneko A, Iio S, Nawa T, Yamada Y, Morishita N, Usui T, Hiramatsu N, Doi Y, Sakakibara M, Imanaka K, Yoshida Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Maesaka K, et al. Among authors: doi y, doi a. PLoS One. 2023 Feb 7;18(2):e0281459. doi: 10.1371/journal.pone.0281459. eCollection 2023. PLoS One. 2023. PMID: 36749777 Free PMC article.
Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
Kurokawa M, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T. Kurokawa M, et al. Among authors: doi y. J Gastroenterol. 2012 May;47(5):577-85. doi: 10.1007/s00535-011-0522-7. Epub 2012 Jan 11. J Gastroenterol. 2012. PMID: 22231575 Clinical Trial.
Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.
Yamada R, Hiramatsu N, Oze T, Morishita N, Harada N, Yakushijin T, Iio S, Doi Y, Yamada A, Kaneko A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, Takehara T; Osaka Liver Forum. Yamada R, et al. Among authors: doi y. J Gastroenterol. 2015 Jul;50(7):785-94. doi: 10.1007/s00535-014-1010-7. Epub 2014 Nov 11. J Gastroenterol. 2015. PMID: 25384794
Impact of branched-chain amino acid supplementation on survival in patients with advanced hepatocellular carcinoma treated with sorafenib: A multicenter retrospective cohort study.
Imanaka K, Ohkawa K, Tatsumi T, Katayama K, Inoue A, Imai Y, Oshita M, Iio S, Mita E, Fukui H, Yamada A, Nakanishi F, Inada M, Doi Y, Suzuki K, Kaneko A, Marubashi S, Ito Y, Fukui K, Sakamori R, Yakushijin T, Hiramatsu N, Hayashi N, Takehara T; Osaka Liver Forum. Imanaka K, et al. Among authors: doi y. Hepatol Res. 2016 Sep;46(10):1002-10. doi: 10.1111/hepr.12640. Epub 2016 Jan 26. Hepatol Res. 2016. PMID: 26690886
Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C.
Tahata Y, Sakamori R, Urabe A, Morishita N, Yamada R, Yakushijin T, Hiramatsu N, Doi Y, Kaneko A, Hagiwara H, Yamada Y, Hijioka T, Inada M, Tamura S, Imai Y, Furuta K, Kodama T, Hikita H, Tatsumi T, Takehara T. Tahata Y, et al. Among authors: doi y. Hepatol Commun. 2018 Aug 6;2(8):884-892. doi: 10.1002/hep4.1206. eCollection 2018 Aug. Hepatol Commun. 2018. PMID: 30094400 Free PMC article.
Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
Morishita N, Sakamori R, Yamada T, Kai Y, Tahata Y, Urabe A, Yamada R, Kodama T, Hikita H, Doi Y, Tamura S, Hagiwara H, Imai Y, Iio S, Tatsumi T, Takehara T. Morishita N, et al. Among authors: doi y. PLoS One. 2020 Jun 16;15(6):e0234811. doi: 10.1371/journal.pone.0234811. eCollection 2020. PLoS One. 2020. PMID: 32544182 Free PMC article.
Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment.
Maesaka K, Sakamori R, Yamada R, Tahata Y, Oshita M, Hagiwara H, Sakakibara M, Tamura S, Hiramatsu N, Inada M, Iio S, Ito T, Yakushijin T, Doi Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Maesaka K, et al. Among authors: doi y. Hepatol Res. 2021 May;51(5):517-527. doi: 10.1111/hepr.13623. Epub 2021 Mar 9. Hepatol Res. 2021. PMID: 33507588
Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals.
Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Oshita M, Ohkawa K, Hijioka T, Fukui H, Ito T, Doi Y, Yamada Y, Yakushijin T, Yoshida Y, Tatsumi T, Takehara T; Osaka Liver Forum. Tahata Y, et al. Among authors: doi y. Aliment Pharmacol Ther. 2021 Nov;54(10):1340-1349. doi: 10.1111/apt.16632. Epub 2021 Oct 7. Aliment Pharmacol Ther. 2021. PMID: 34618934
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.
Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T. Myojin Y, et al. Among authors: doi y, doi a. Aliment Pharmacol Ther. 2022 Feb;55(4):422-433. doi: 10.1111/apt.16691. Epub 2021 Nov 23. Aliment Pharmacol Ther. 2022. PMID: 34812502 Clinical Trial.
2,073 results